MENU

4882 東証マザーズ(医薬品)

ペルセウスプロテオミクス

新規上場会社紹介レポート

(公開日 2021.06.25)

PDFを開く

Perseus Proteomics(4882 TSE Mothers)

English Summary (PDF)

+English Summary on This Page

Developing Antibody Drugs Centering on Cancer Treatment Drugs
Perseus Proteomics was established with an aim for the medical application of antibodies using the technologies of protein expression and antibody generation, which were developed by the Laboratories for Systems Biology and Medicine (LSBM) of the Research Center for Advanced Science and Technology at the University of Tokyo. It is engaged in research and development of antibody drugs against diseases centering on cancers as well as related operations.

Antibodies are proteins that specifically bind with antigens (materials to which immune reactions are seen) in a one-to-one manner, and by using this unique nature of the antibodies, they are applied to drugs for diagnosing/treating diseases such as cancers and infections. As an antibody drug makes a pinpoint attack against an antigen that causes the disease, a high therapeutic effect and reduction in side effects can be expected.

The company has strengths in discovering and analyzing target materials, etc. that appear on the surface of cancer cells, etc. as well as technologies for generating and screening antibodies that specifically bind with such materials.

The company is engaged in the three operations described below.
(1) Drug Discovery
By acquiring highly functional antibodies using the company’s technologies for target discovery and antibody generation and adding genetic engineering modification or chemical modification as needed, the company conducts research and development of drug candidates including antibody-drug conjugates (ADCs or armed antibodies) which bind antibodies with other preparations.

(2) Antibody Research Support
The company is conducting antibody generation, contracted research, sequencing analysis and other antibody research support for academic institutions and pharmaceutical companies.

(3) Sales of Antibodies and Reagents
The company sells nuclear receptor antibodies, which act as biomarkers for cancers and various other diseases, as research reagents for researchers in Japan and overseas.

概要(レポートから抜粋)

ペルセウスプロテオミクス(以下、同社)は、東京大学先端科学技術研究センター・システム生物医学ラボラトリーで開発された蛋白質発現・抗体作製技術を基盤として抗体の医療への活用を目指して設立され、がんを中心とした抗体医薬品の研究開発、関連業務を行っている。

抗体は、抗原(免疫反応を示す物質)に1対1の関係で特異的に結合する蛋白質であり、この抗体の特異的性質を利用してがんや感染症等の疾患を診断・治療する医薬品に応用される。

抗体医薬品は疾患をもたらす抗原をピンポイントで狙い撃ちするため、高い治療効果と副作用の軽減が期待できる。

同社は、がん細胞等の表面に現れる標的物質等の探索・解析と、それに特異性を持って結合する抗体の作製、スクリーニング技術に強みを持っている。

この企業の関連キーワード

ペルセウスプロテオミクス

企業情報・その他のレポートはこちら

検索

アプリ

iPhone/Android/iPad版無料アプリ
「アナリストレポートライブラリ」

無料アプリでアナリストレポート情報を素早く取得

  • Google play
  • App Store